Cardiol Therapeutics Raises $11.4M, Extends Cash Runway
Ticker: CRDL · Form: 6-K · Filed: Oct 21, 2025 · CIK: 1702123
Sentiment: bullish
Topics: financing, cash-runway, biotech
TL;DR
Cardiol just closed an $11.4M financing, pushing their cash runway to Q3 2027. Big win for runway.
AI Summary
Cardiol Therapeutics Inc. announced on October 21, 2025, that it has successfully completed a financing round, raising US$11.4 million. This funding is expected to extend the company's cash runway into the third quarter of 2027, providing significant financial stability for its operations and development plans.
Why It Matters
This financing provides Cardiol Therapeutics with the capital needed to continue its research and development efforts, potentially advancing its drug candidates and improving its financial outlook.
Risk Assessment
Risk Level: medium — While the financing provides runway, the company operates in the biotech sector, which is inherently risky due to clinical trial outcomes and regulatory hurdles.
Key Numbers
- US$11.4M — Financing Raised (Provides capital for operations and development.)
- Q3 2027 — Cash Runway Extended To (Indicates financial stability for future operations.)
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Registrant
- US$11.4 million (dollar_amount) — Financing amount raised
- Q3 2027 (date) — Extended cash runway
FAQ
What is the primary purpose of the US$11.4 million financing?
The filing indicates the financing is to extend the company's cash runway into Q3 2027, supporting ongoing operations and development.
When was the news release regarding the financing filed?
The news release, Exhibit 99.1, is dated October 21, 2025.
What is Cardiol Therapeutics Inc.'s principal executive office address?
The principal executive offices are located at 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5.
Which form does Cardiol Therapeutics Inc. file annually?
Cardiol Therapeutics Inc. files an annual report under Form 40-F.
What is the SIC code for Cardiol Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for Cardiol Therapeutics Inc. is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 174 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2025-10-21 07:30:13
Key Financial Figures
- $11.4 Million — 2025 - Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into
Filing Documents
- form6k.htm (6-K) — 5KB
- exhibit99-1.htm (EX-99.1) — 13KB
- exhibit99-1xu001.jpg (GRAPHIC) — 7KB
- 0001062993-25-016232.txt ( ) — 29KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: October 21, 2025 By: /s/ Chris Waddick Chris Waddick Title: Chief Financial Officer